1. Bridgeman, Mary Barna PharmD, BCPS, BCGP
  2. Dalal, Kavitha S. PharmD

Article Content

CAN YOU IDENTIFY these drugs indicated for central nervous system disorders? To find out, match each brand name in Section I with its generic name in Section II.


Section I

_____ 1. Briviact (UCB, Inc.)


_____ 2. Aimovig (Amgen)


_____ 3. Austedo (Teva Pharmaceuticals USA, Inc.)


Section II

a. brivaracetam. This medication is indicated to treat partial-onset seizures in patients age 4 years or older as either monotherapy or in conjunction with other medications. It is available in three forms-oral tablets, oral solution, and I.V. injection-but the I.V. formulation is indicated only for patients age 16 and older because its safety in younger patients has not been established. Monitor patients for suicidal behaviors or thoughts; other neurologic or psychiatric adverse reactions such as sedation; and hypersensitivity reactions.


b. erenumab-aooe. Administered as a once-monthly subcutaneous injection, this drug is prescribed for preventive treatment of episodic or chronic migraine in adults. This monoclonal antibody, which works as an antagonist to the calcitonin gene-related peptide receptor, represents a new class of medications indicated for migraine relief. Teach patients to self-administer subcutaneous injections in the abdomen, thigh, or upper arm via use of a prefilled autoinjector syringe.


c. deutetrabenazine. Granted Orphan Drug Designation by the FDA, deutetrabenazine is the second medication approved for treatment of the spastic, jerking movements (chorea) associated with Huntington disease and is also approved to treat tardive dyskinesia in adults. This medication is administered as a once-daily oral tablet and carries a Boxed Warning about the risk of suicidality and depression in patients with Huntington disease.


Resources available upon request


ANSWERS: 1a, 2b, 3c